Trial Profile
Randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of GW679769 (30mg and 90mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Casopitant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors GSK
- 22 Apr 2008 New trial record.